Wacker Biosolutions to focus on biotechnology
Wacker Fine Chemicals becomes Wacker Biosolutions and concentrates on biotechnology
Wacker Biosolutions will concentrate on building its business in three main areas, including pharmaceuticals, alongside its existing portfolio of fine chemicals and chemical intermediates. Its biotech products include cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins.
The Munich-based firm is currently extending process development and production capacities for the manufacture of pharmaceutical proteins at Wacker Biotech in Jena, Germany.
Wacker aims to offer tailored complete solutions to customers, taking advantage of the synergies between its chemical and biotech expertise. It sees potential in providing innovative products and technologies in the budding market for bioengineered products.
"This reorganisation lays further foundations for Wacker's future success in the growing field of biotechnology," said Gerhard Schmid, senior vice president of Wacker Biosolutions.
Over the past few years, Wacker has posted high double-digit growth with biotech products such as cyclodextrins and cysteine. The group sees future global-market potential in pharmaceutical actives, food additives and agrochemicals.
You may also like
Trending Articles
You may also like
Manufacturing
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs
Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Portable gas detection in the pharmaceutical sector
Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
New legal duties for QPs in decentralised manufacturing
In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Manufacturing
FDA escalates action against Dabur India over systemic data-integrity and cGMP failures
The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies
Manufacturing
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction
The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows